Phase II study of antineoplastons A10 and AS2-1 in patients with macroglobulinemia of Waldenstrom
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 29 Jan 2018 Status changed from active, no longer recruiting to withdrawn prior to enrolment as no participants enrolled.
- 01 Oct 2005 New trial record.